Will your pharma product launch process set the pace for lasting impact?
In pharma, launch isn’t the finish line—it’s closer to the starting line. A successful pharma product launch depends on how well medical affairs and commercial teams align to optimize insights, build advocacy, and refine strategy in real time.
Bringing a pharmaceutical product to market is a complex, high-stakes process. Since first-year performance often predicts long-term success (we’ve all seen the data), it is critical to ensure a data-driven, insights-led approach is woven into every pharma product launch strategy. Medical affairs teams play a vital role in shaping the scientific narrative, engaging KOLs, and ensuring clinical differentiation, while commercial teams focus on market positioning, prescriber adoption, and competitive strategy.
When these functions align, companies can reduce risk, maximize impact, and drive a more successful launch.
Achieving pharma product launch success requires more than just a traditional go-to-market plan. Companies must integrate real-time market intelligence, cross-functional collaboration, and proactive stakeholder engagement to navigate challenges and seize opportunities. Yet, despite meticulous planning, pharma teams encounter major roadblocks that can derail even the most promising pharmaceutical product launch.
Here’s how to overcome three of the biggest challenges that threaten launch success.
Challenge #1: Accurately estimating market potential early in the pharma product launch process
One of the most common reasons a drug underperforms at launch is an inadequate understanding of market dynamics, stakeholder needs, and competitive positioning. Companies often underestimate the difficulty of shifting prescriber habits and overcoming patient adoption barriers. Without comprehensive insights into HCP, payer, and patient perspectives, these challenges become even greater.
When launch decisions are based on outdated, incomplete, or siloed data, pharma teams risk misaligning their product strategy with real-world market expectations. This misalignment can impact everything from pricing and access to prescriber uptake and patient adherence—ultimately leading to an underwhelming launch.
Solution: Cross-functional insights that inform strategic planning
A successful launch begins long before commercialization. Medical affairs and commercial teams must work together to continuously refine their understanding of the market, stakeholders, and competitive landscape. This means leveraging real-time insights to answer critical questions, such as:
- What unmet needs exist in the patient and physician communities?
- How do KOLs and prescribers perceive the clinical and non-clinical benefits of the product?
- What market access and regulatory hurdles need to be addressed?
- How will the product differentiate itself in an increasingly competitive landscape?
An insights-driven pharma product launch approach enables teams to close knowledge gaps, identify key stakeholders, and develop a data-backed strategy that aligns with both scientific evidence and commercial objectives. By integrating ongoing KOL engagement, real-world evidence, and competitive intelligence into launch planning, companies can proactively adjust their strategy—reducing risk and maximizing their product’s potential.
Challenge #2: Standing out in a crowded therapeutic market
Competition in the pharmaceutical industry is more intense than ever, and significant ROI is far from guaranteed. Deloitte reports that average forecasted peak sales per asset fell by more than 30% in a single decade, from $520 million in 2013 to $353 million in 2023. While forecasts have begun to recover in the post-pandemic era, R&D costs per pipeline asset continue to climb, putting further pressure on margins.
This reflects rising competition, payer scrutiny, and the shift toward smaller specialty markets. With new therapies entering crowded indications and competing for the same prescriber and patient attention, companies must ensure strong differentiation from day one.
In this environment, clinical data from Phase III trials alone is no longer enough to secure adoption. HCPs and payers now expect real-world evidence, personalized engagement, and strong advocacy from trusted experts. Without a well-defined differentiation strategy, companies risk losing traction to competitors before their pharmaceutical product launch even gains momentum.
Solution: Build advocacy and communicate your product’s full value proposition
ToTo stand out in a competitive launch environment, both medical affairs and commercial teams must collaborate to define and communicate not just the clinical advantages, but also the broader impact of a new therapy. This means going beyond efficacy and safety data to emphasize:
- Differentiation: Provide compelling scientific evidence, real-world data, and KOL validation that highlights how the product improves patient outcomes compared to existing options.
- Prescriber targeting: Identify and engage the right HCPs and integrated delivery networks to ensure the product reaches prescribers most likely to adopt and advocate for it.
- Personalized content: A one-size-fits-all approach is no longer effective. Engaging stakeholders with tailored, insights-driven messaging helps ensure that physicians, payers, and patients understand the product’s unique value.
- Clinician support: Prescriber adoption is influenced not just by clinical data but also by the support and resources provided by the pharmaceutical company. Addressing physician concerns, facilitating peer-to-peer exchanges, and providing medical education opportunities can build long-term loyalty and advocacy.
By leveraging real-time insights, digital engagement, and KOL advocacy, pharma teams can refine their strategy as market conditions evolve—ensuring that their product launches successfully and continues to gain traction in a competitive space.
“You own a medical narrative by making sure that it’s grounded, and based on actual data. It needs to be data-driven, but it also needs to resonate. The data should be grounded in what the HCP, patient, and caregiver communities care about.”
– Sylke Anderson, Senior Director, Client Strategy Lead, Within3
Challenge #3: Barriers to patient and clinician access post-launch
According to a Deloitte study, nearly half of the products that fell short of their first-year forecast faced market access issues, such as:
- Unfavorable placement
- Exclusion from formulary
- Use of formulary restrictions
- Lack of health-economic evidence in support of pricing
- Higher-than-expected expenses on rebates or discounts
When market access is limited, both patients and clinicians lose trust that they’ll be able to obtain the drug. This reduced confidence can create a ripple effect, jeopardizing a new product’s ability to succeed.
“It’s really important for medical affairs to partner not only with our traditional medical experts or key opinion leaders, but with a broader range of stakeholders such as payers, patient groups, and societies so that we really understand the unmet needs and we really understand where the patient access barriers are.”
– Anne Wiland, Global Head Medical Excellence, Oncology at Novartis
Solution: Make market access a cornerstone of strategic product launch planning
Addressing market access challenges requires early integration of access strategy into the overall pharma product launch process. Medical affairs and commercial teams must collaborate to build a compelling value narrative backed by clinical, economic, and real-world evidence. A strong market access strategy should include:
- Early and ongoing payer engagement: Understanding payer priorities and reimbursement trends helps teams anticipate potential barriers and proactively address them.
- Robust Health-Economic and Outcomes Research (HEOR): Providing clear, data-driven justification for a product’s price and value proposition is crucial for securing favorable coverage decisions.
- Cross-functional alignment with commercial and medical affairs: Medical affairs plays a key role in generating real-world evidence and facilitating discussions with payers and policy influencers.
- Flexibility to adapt to evolving market conditions: Continuous insights from prescribers, patients, and payers allow teams to refine their approach and stay ahead of competitive and regulatory shifts.
Ready to take control of your pharma product launch success?
Successfully launching a new pharmaceutical product requires more than just a great clinical profile—it demands strategic execution, cross-functional collaboration, and continuous market adaptation. Medical affairs and commercial teams must work together to generate actionable insights, build strong stakeholder advocacy, and proactively address market access challenges to maximize launch success.
By taking an insights-driven approach, pharma companies can navigate the complexities of launch execution, ensuring their product reaches the right patients, gains prescriber trust, and stands out in an increasingly competitive landscape.
Don’t let challenges during the product launch process derail your success.
Want to learn how to plan smarter, more impactful pharma product launches?
Book a demo of the Within3 Launch Intelligence™ platform today.
